热门资讯> 正文

周六报道，Cogent Biosciences在AAAAI 2026上重点介绍了SUMMIT数据，Bezuclastini在48周时使平均TSB降低-32.0个百分点，99%的人血清胰蛋白酶降低了至少50%

2026-03-02 15:51

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib's potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。